Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:27 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 11,377 matching trials from the live ClinicalTrials.gov search.
Conditions
Neurofibromatosis Type 2
Interventions
REC-2282, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 8 more
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
tipifarnib, etoposide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
70 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Colorectal Cancer
Interventions
FOLFIRI regimen, bevacizumab, cetuximab, dulanermin, irinotecan
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
10
States / cities
Los Angeles, California • Redlands, California • San Francisco, California + 7 more
Conditions
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Conditions
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
Interventions
ABM-168
Drug
Lead sponsor
ABM Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Francisco, California • Indianapolis, Indiana • New Brunswick, New Jersey + 3 more
Conditions
Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Interventions
INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more
Conditions
Hepatic Impairment
Interventions
Betrixaban
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Hialeah, Florida
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GNS-3545, GNS-3545 Placebo
Drug
Lead sponsor
Genosco Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
Conditions
Neoplasms, Tumor
Interventions
IMC-TR1
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas • San Antonio, Texas
Conditions
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions
Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • Minneapolis, Minnesota
Conditions
Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia, Myeloma, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Recurrent Acute Myeloid Leukemia, Adult, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Interventions
mycophenolate mofetil, Sargramostim, Filgrastim
Drug · Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Traumatic Brain Injury
Interventions
Blood draw
Other
Lead sponsor
Banyan Biomarkers, Inc
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Gainesville, Florida • Orlando, Florida • Detroit, Michigan + 3 more
Conditions
Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
Indoximod, Ipilimumab, Nivolumab, Pembrolizumab
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of KINE-101 in Healthy Volunteers

NCT07343323
Conditions
Healthy Volunteers
Interventions
KINE-101, Placebo
Drug
Lead sponsor
Kine Sciences Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP)

NCT00178659
Conditions
Brain Injuries, Traumatic, Traumatic Brain Injury
Interventions
Blood/saliva samples for protein/molecular analysis
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
14 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Parkinson Disease
Interventions
B-CIT and SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Active, not recruiting Phase 2 Interventional Results available

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT04126070
Conditions
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
Interventions
Androgen Deprivation Therapy, Nivolumab, Docetaxel
Drug
Lead sponsor
Xiao X. Wei, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Conditions
Pancreatic Cancer, Mesothelioma, Ovarian Cancer, Non-Small Cell Lung Cancer
Interventions
MORAb-009
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine, Bendamustine
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
Interventions
Cyclophosphamide, CART-BCMA, huCART19
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Conditions
Lymphatic Malformation
Interventions
CERC-006
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 31 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio
Conditions
Schizophrenia
Interventions
CVL-231
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts